Wanbury Limited (NSE:WANBURY)
265.00
+6.85 (2.65%)
Jun 5, 2026, 3:29 PM IST
Wanbury Revenue
In the fiscal year ending March 31, 2026, Wanbury had annual revenue of 6.51B INR with 8.50% growth. Wanbury had revenue of 1.65B in the quarter ending March 31, 2026, a decrease of -4.56%.
Revenue
6.51B
Revenue Growth
+8.50%
P/S Ratio
1.38
Revenue / Employee
4.71M
Employees
1,382
Market Cap
9.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 6.51B | 510.26M | 8.50% |
| Mar 31, 2025 | 6.00B | 224.42M | 3.88% |
| Mar 31, 2024 | 5.78B | 780.91M | 15.63% |
| Mar 31, 2023 | 5.00B | -115.39M | -2.26% |
| Mar 31, 2022 | 5.11B | 1.19B | 30.23% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Indoco Remedies | 18.45B |
| Solara Active Pharma Sciences | 13.75B |
| Windlas Biotech | 9.04B |
| Ind-Swift Laboratories | 6.88B |
| Sigachi Industries | 4.86B |
| Beta Drugs | 3.85B |
| Jagsonpal Pharmaceuticals | 2.87B |
| Sakar Healthcare | 2.54B |
Wanbury News
- 4 months ago - Wanbury begins commercial production of high-potent anaesthetic API - Business Upturn
- 8 months ago - Wanbury implements SAP S/4HANA ERP to drive future ready operations - Business Upturn
- 1 year ago - Wanbury launches next-gen iron supplement ‘C RED’ to revolutionize anemia management in India - Business Upturn
- 1 year ago - Wanbury receives GMP certification from ANVISA for Patalganga facility - Business Upturn
- 1 year ago - Wanbury’s Tanuku facility in Andhra Pradesh completes ANVISA inspection with zero observations - Business Upturn
- 1 year ago - Wanbury launches Wanbury C-RED and Ketamine Hydrochloride - Business Upturn
- 1 year ago - Wanbury shares rise 2.56% following company refinances Rs 95 crore NCDs, reducing interest costs - Business Upturn
- 1 year ago - Wanbury secures lower-cost refinancing for outstanding debentures - Business Upturn